Literature DB >> 32247201

Nitric oxide-induced stromal depletion for improved nanoparticle penetration in pancreatic cancer treatment.

Xiaohui Chen1, Fan Jia1, Yongzhou Li2, Yongyan Deng1, Yue Huang1, Weifeng Liu3, Qiao Jin4, Jian Ji1.   

Abstract

Abundant desmoplastic stroma, which typically exists in pancreatic ductal adenocarcinoma (PDAC), can act as a natural protective physical barrier rendering insufficient drug delivery and penetration. To address this issue, we herein report a two-step sequential delivery strategy for enhanced pancreatic cancer therapy. In this sequential strategy, the nitric oxide (NO) donor S-nitroso-N-acetylpenicillamine (SNAP) loaded liposomes (Lip-SNAP) were firstly delivered to pancreatic stellate cells (PSCs) in tumor tissue to inhibit the production of dense stroma, by inhibiting the expression of TGF-β1 and its downstream profibrotic signal transduction. Therefore, the PSC-mediated desmoplastic reaction could be suppressed by inhibiting the expression of fibronectin, α-SMA and collagen. The gemcitabine (GEM) loaded liposomes (Lip-GEM) were administrated subsequently. The enhanced intratumoral penetration of Lip-GEM was then achieved due to the stromal disruption in consequence of NO treatment, thus significantly improving the drug delivery efficiency. The tumor growth inhibition of the two-step sequential delivery of Lip-SNAP and Lip-GEM was investigated on both subcutaneous and orthotopic tumor mouse models, to show the remarkably improved therapeutic efficacy of GEM. Such NO-induced stromal depletion provides a general strategy to overcome the blockage of desmoplastic stroma on other therapeutic agents.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Liposomes; Nitric oxide; Pancreatic cancer; Stroma depletion; Tumor penetration

Mesh:

Substances:

Year:  2020        PMID: 32247201     DOI: 10.1016/j.biomaterials.2020.119999

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  12 in total

1.  Synergistic Therapy Using Doxorubicin-Loading and Nitric Oxide-Generating Hollow Prussian Blue Nanoparticles with Photoacoustic Imaging Potential Against Breast Cancer.

Authors:  Jijun Fu; Qianni Wu; Yuanye Dang; Xueping Lei; Guining Feng; Mingyue Chen; Xi-Yong Yu
Journal:  Int J Nanomedicine       Date:  2021-08-31

Review 2.  Opportunities for Nitric Oxide in Potentiating Cancer Immunotherapy.

Authors:  Jihoon Kim; Susan N Thomas
Journal:  Pharmacol Rev       Date:  2022-10       Impact factor: 18.923

Review 3.  Gasotransmitters in the tumor microenvironment: Impacts on cancer chemotherapy (Review).

Authors:  Abbas Salihi; Mohammed A Al-Naqshabandi; Zhikal Omar Khudhur; Zjwan Housein; Harmand A Hama; Ramyar M Abdullah; Bashdar Mahmud Hussen; Twana Alkasalias
Journal:  Mol Med Rep       Date:  2022-05-26       Impact factor: 3.423

4.  Predicting Gemcitabine Delivery by 18F-FAC PET in Murine Models of Pancreatic Cancer.

Authors:  James Russell; Milan Grkovski; Isabella J O'Donoghue; Teja M Kalidindi; Nagavarakishore Pillarsetty; Eva M Burnazi; Amanda Kulick; Amber Bahr; Qing Chang; H Carl LeKaye; Elisa de Stanchina; Kenneth H Yu; John L Humm
Journal:  J Nucl Med       Date:  2020-07-09       Impact factor: 11.082

Review 5.  Applications of Surface Modification Technologies in Nanomedicine for Deep Tumor Penetration.

Authors:  Zimu Li; Xiaoting Shan; Zhidong Chen; Nansha Gao; Wenfeng Zeng; Xiaowei Zeng; Lin Mei
Journal:  Adv Sci (Weinh)       Date:  2020-11-27       Impact factor: 16.806

Review 6.  Combining Nanotechnology and Gas Plasma as an Emerging Platform for Cancer Therapy: Mechanism and Therapeutic Implication.

Authors:  Milad Rasouli; Nadia Fallah; Sander Bekeschus
Journal:  Oxid Med Cell Longev       Date:  2021-10-27       Impact factor: 6.543

7.  Upconversion nanoparticles regulated drug & gas dual-effective nanoplatform for the targeting cooperated therapy of thrombus and anticoagulation.

Authors:  Shichen Liu; Yao Sun; Teng Zhang; Longtao Cao; Zhiwei Zhong; Haoxin Cheng; Qingqing Wang; Zhuang Qiu; Weimin Zhou; Xiaolei Wang
Journal:  Bioact Mater       Date:  2022-03-17

Review 8.  Emerging pro-drug and nano-drug strategies for gemcitabine-based cancer therapy.

Authors:  Haijie Han; Su Li; Yueyang Zhong; Yue Huang; Kai Wang; Qiao Jin; Jian Ji; Ke Yao
Journal:  Asian J Pharm Sci       Date:  2021-07-01       Impact factor: 6.598

Review 9.  Near-infrared light-triggered nano-prodrug for cancer gas therapy.

Authors:  Runcong Liu; Yongjun Peng; Ligong Lu; Shaojun Peng; Tianfeng Chen; Meixiao Zhan
Journal:  J Nanobiotechnology       Date:  2021-12-23       Impact factor: 10.435

Review 10.  Nanomedicine in Pancreatic Cancer: Current Status and Future Opportunities for Overcoming Therapy Resistance.

Authors:  Michelle K Greene; Michael C Johnston; Christopher J Scott
Journal:  Cancers (Basel)       Date:  2021-12-07       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.